Procognitive activity in rats of 3-furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the α7 nicotinic acetylcholine receptor

A Potasiewicz[1], T Kos[1], F Ravazzini[2], G Puia[2], H R. Arias[3], P Popik[1], A Nikiforuk[1,*]

[1]Behavioral Neuroscience and Drug Development, Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna Street, 31-343 Kraków, Poland.

[2]Department of Life Science, University of Modena and Reggio Emilia, Modena, Italy.

[3]Department of Medical Education, California Northstate University College of Medicine, CA 95757, USA.

Correspondence*:

Agnieszka Nikiforuk, Institute of Pharmacology Polish Academy of Sciences, 12 Smetna Street, 31-343 Krakow, Poland, e-mail: nikifor@if-pan.krakow.pl tel: +48+12 6623374 fax: +48+12 6374500

Running title: Procognitive effects of PAM-2

BACKGROUND AND PURPOSE.

Alpha 7 nicotinic acetylcholine receptors (α7-nAChRs) may represent useful targets for cognitive improvement. The aim of this study is to compare the procognitive activity of selective α7-nAChR ligands, including the partial agonists, DMXBA and A-582941, as well as the positive allosteric modulator, 3-furan-2-yl-N-p-tolyl-acrylamide (PAM-2).

EXPERIMENTAL APPROACH

The attentional set-shifting task (ASST) and the novel object recognition task (NORT) in rats, were used to evaluate the procognitive activity of each ligand [i.e., PAM-2 (0.5, 1.0, and 2.0 mg·kg^{-1}), DMXBA and A-582941 (0.3 and 1.0 mg·kg^{-1})], in the absence and presence of methyllycaconitine (MLA), a selective competitive antagonist. To determine potential drug interactions, an inactive dose of PAM-2 (0.5 mg·kg^{-1}) was co-injected with inactive doses of either agonist [DMXBA: 0.1 (NORT) and 0.3 mg·kg^{-1} (ASST); A-582941: 0.1 mg·kg^{-1}].

KEY RESULTS

Our results reveal that PAM-2, DMXBA, and A-582941 improve cognition in a MLA-dependent manner, indicating that the observed activities are mediated by α7 nAChRs. Interestingly, the co-injection of inactive doses of PAM-2 and DMXBA or A-582941 also improves cognition, suggesting drug interactions. Moreover, PAM-2 reversed the scopolamine-induced NORT deficit. The electrophysiological results also support the view that PAM-2 potentiates the α7 nAChR currents elicited by a fixed concentration (3 μM) of DMXBA with apparent $EC_{50} = 34 \pm 3$ μM and $E_{max} = 225 \pm 5$ %.

CONCLUSIONS AND IMPLICATIONS

Our results support the view that α7 nAChRs are involved in cognition processes and that PAM-2 is a novel promising candidate for the treatment of cognitive disorders.

Abbreviations

AChR, nicotinic acetylcholine receptor; AD, Alzheimer's disease,; PAM, positive allosteric modulator; PAM-2, 3-furan-2-yl-N-p-tolyl-acrylamide; MLA, methyllycaconitine; ASST, attentional set-shifting task; SD, simple discrimination; CD, compound discrimination; Rev, reversal of discrimination; ID, intra-dimensional; ED, extra-dimensional; NORT, novel object recognition task; ITI, inter-trial interval; SCOP, scopolamine; T1, familiarisation trial; T2, retention trial; E, exploration time; DI, discrimination index; E_{max}, ligand efficacy; apparent EC_{50}, enhancement potency; n_H, Hill coefficient; r^2, goodness of fit.

Introduction

The α7 nicotinic acetylcholine receptor (AChR) is member of the Cys-loop ligand-gated ion channel family (receptor nomenclature follows Alexander et al. (2013a)). α7 AChRs are one of the most abundant subtypes expressed in brain areas (e.g., hippocampus, amygdala, midbrain, and prefrontal cortex) involved in important physiological functions such as memory, cognition, and different types of learning tasks (reviewed in (Freedman, 2014)). Important roles in the development of neurological diseases with cognitive impairments such as Alzheimer's disease (AD), schizophrenia, and Huntington's disease, have been assigned to these AChRs as well. In this regard, a great effort has been made lately in the synthesis and functional characterization of selective α7 AChR ligands, including agonists, antagonists, and positive allosteric modulators (PAMs) (Arias *et al.*, 2010;Tietje *et al.*, 2008; reviewed in: Freedman, 2014;Pohanka, 2012; Arias, 2011) as attempts to develop treatment for these diseases.

Allosteric modulation has been proposed as an advantageous therapeutic strategy compared to the orthosteric activation of α7 AChRs (Uteshev, 2014;Williams *et al.*, 2011). The structural diversity of allosteric sites allows for greater receptor selectivity. Since PAMs do not directly activate AChRs the risk of overdosing is limited. Since PAMs do not compete with the agonist binding sites, this approach may be particularly beneficial in schizophrenic patients who usually smoke more tobacco than the general population. Furthermore, type II PAMs, which are less prone to cause prolonged α7 nAChR desensitisation and even reactivate desensitized nAChRs, do not produce the loss of function that may occur after the chronic administration of an agonist.

Recently, a series of PAMs with selectivity for the α7 AChR has been synthesised and pharmacologically characterized (Arias *et al.*, 2011). Among them, 3-furan-2-yl-N-p-tolyl-acrylamide (PAM-2) presents antidepressant (Arias *et al.*, 2015;Targowska-Duda *et al.*, 2014a), promnesic and anxiolytic (Targowska-Duda *et al.*, 2014b), and antinociceptive and anti-inflammatory activity (Bagdas *et al.*, 2015) in mice. To complete these preclinical studies, and to determine the procognitive activity of PAM- 2, two animal tests, namely the attentional set-shifting task (ASST) (Nikiforuk *et al.*, 2010) and the novel object recognition task (NORT) (Nikiforuk *et al.*, 2013), were used on male rats.

The ASST is a rodent version of the Intra/Extra Dimensional set-shifting task (Roberts *et al.*, 1988) that assesses cognitive flexibility (i.e., the ability to modify behaviour in response to the altering relevance of stimuli). In this paradigm, rats must select a bowl containing a food reward based on the ability to discriminate the odours or the media covering the bait (Birrell & Brown, 2000). The ASST requires rats to initially learn a rule and form an attentional "set" within the same stimulus dimensions. At the extra-dimensional (ED) shift stage, the essential phase of the task, animals must switch their attention to a previously irrelevant stimulus dimension and, for example, discriminate between the odours and not between the media covering the bait. The animal's performance at the ED stage is considered an index of cognitive flexibility and depends on the medial prefrontal cortex (mPFC) (Birrell & Brown, 2000).

The NORT in rodents has been increasingly used as an ethologically relevant paradigm for studying visual episodic memory (Ennaceur & Delacour, 1988). This task is based on the spontaneous exploration of novel and familiar objects. Successful object recognition is displayed by more time spent interacting with the novel object in the retention trial. Introducing longer inter-trial intervals (e.g., 24 h in the present experiments) abolishes object discrimination. This delay-induced deficit closely resembles natural forgetting.

The procognitive activity elicited by PAM-2 was compared to that for two partial agonists with selectivity for the α7 AChR, namely DMXBA (also named GTS-21) (reviewed in (Freedman, 2014) and A-582941 (Tietje *et al.*, 2008), and the observed drug activities challenged by the selective competitive antagonist, methyllycaconitine (MLA) (Arias *et al.*, 2010). To determine whether drug interactions occur, the combination of drugs at inactive doses was also tested. Moreover, the ability of PAM-2 to ameliorate the scopolamine-induced object recognition deficit was assessed. Finally, electrophysiological experiments using SH-SY5Y-α7 cells were performed to determine the potentiation of DMXBA-evoked α7 nAChR currents elicited by PAM-2.

Materials and Methods

Animals

Male Sprague-Dawley rats (Charles River, Germany), weighing 200-250 g on arrival, were housed in a temperature-controlled (21 ± 1 °C) and humidity-controlled (40–50%) colony room under a 12 h/12 h light/dark cycle (lights on at 06:00 am). For the ASST experiments, rats were individually housed with a mild food restriction (17 g of food pellets per day) for at least one week prior to testing. For the NORT studies, rats were group-housed (5 rats/cage) with free access to food and water. Behavioural testing was performed during the light phase of the light/dark cycle. The experiments were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals and were approved by the Ethics Committee for Animal Experiments, Institute of Pharmacology (Krakow, Poland).

Attentional set-shifting task

A detailed description of the apparatus and procedure has been provided previously (Nikiforuk *et al.*, 2010). Briefly, rats were presented with two ceramic pots, with only one pot baited with a food reward (Honey Nut Cheerio, Nestle®). Animals had to retrieve the Cheerio on the basis on their ability to discriminate the odours associated with the pot and the digging media that covered Cheerio bait in the pot.

The procedure entailed three days for each rat: habituation, training and testing. During a single test session, rats performed a series of 7 discriminations. In the simple discrimination involving only one stimulus dimension, the pots differed along one of two dimensions (e.g., digging medium). For the compound discrimination (CD), the second (irrelevant) dimension (i.e., odour) was introduced but the correct and incorrect exemplars of the relevant dimension remained constant. For the reversal of this discrimination (Rev 1), the exemplars and relevant dimension were unchanged but the previously correct exemplar was now incorrect and vice versa. The intra-dimensional (ID) shift was then presented, consisting of new exemplars of both the relevant and irrelevant dimensions with the relevant dimension remaining the same as previously. The ID discrimination was then reversed (Rev 2) so that the formerly positive exemplar became the negative one. This series of discriminations serves to progressively form an attentional set. For the extra-dimensional (ED) shift, a new pair of exemplars was again introduced, but this time a relevant dimension was also changed. At this essential phase of the task, animals must switch their attention to a previously irrelevant stimulus dimension and, for example, discriminate between the odours and not between the media covering the bait. Finally, the last phase was the reversal (Rev 3) of the ED discrimination. The first four trials at the beginning of each discrimination phase were a discovery period (not included in six trials to criteria). In subsequent trials, an incorrect choice was recorded as an error.

Total number of animals used was N=198. All animals were tested once.

Novel object recognition task

Apparatus. Rats were tested in a dimly lit (25 Lux) open field made of dull grey plastic (length x width x height: 66 x 56 x 30 cm).

Procedure. Rats were habituated to the arena (without any objects) for 5 min 24 h before testing (Nikiforuk *et al.*, 2013). The test consisted of two 3-min trials separated by an inter-trial interval (ITI) of 24 h (or 60 min in the scopolamine study). During the first trial (familiarisation, T1), two identical objects (A1 and A2) were presented in opposite corners, approximately 10 cm from the walls of the open field. In the second trial (retention, T2), one of the objects was replaced by a novel one (A = familiar, and B = novel). The objects used were a glass bulb filled with gravel and a plastic bottle filled with sand. The height of the objects was comparable (~12 cm), and they were heavy enough to not be displaced by the animals. Half of the animals from each group received the glass bulb as a novel object, and the other half received the plastic bottle. The location of the novel object in the recognition trial was randomly assigned for each rat. Exploration of an object was defined by looking, licking, sniffing or touching the object while sniffing but not leaning against, standing or sitting on the object. Any rat that spent less than 5 s exploring the two objects within 3 min of T1 or T2 was eliminated from the study. The behaviour was recorded by the camera placed above the arena, and connected to the Any-maze® tracking system (Stoelting Co., Illinois, USA), which measured automatically the distance travelled by an animal. The experimenter manually assessed exploratory activity of animals. Based on the exploration time (E) of the two objects in the retention trial, a discrimination index (DI) was calculated as $(E_B-E_A)/(E_A+E_B)$.

Total number of animals used was N=180. Each rat was tested twice, with a 7-day washout period between each of two tests. No animal received the same treatment twice.

Drugs

PAM-2, synthesised as in Bagdas et al (2015), was suspended in 1% Tween 80 (Sigma–Aldrich, Poznan, Poland) in saline solution, whereas A-582941, DMXBA (GTS-21) (Tocris, Bristol, UK) and scopolamine (Sigma–Aldrich, Poznan, Poland) were dissolved in distilled water. Methyllycaconitine citrate (MLA) (Ascent Scientific, Bristol, UK) was dissolved in distilled water, and the solution was neutralised with 0.1 N NaOH. Drugs or vehicle (physiological saline) were administered in a volume of 1 mL·kg^{-1} of body weight. Fetal bovine serum (FBS) and trypsin/EDTA were purchased from Gibco BRL (Paisley, UK). Geneticin and neomycin were obtained from Tocris Bioscience (Ellisville, MO, USA). Salts were of analytical grade. The drug/molecular target nomenclature used in this manuscript conforms to British Journal of Pharmacology's Concise Guide to PHARMACOLOGY (Alexander *et al.*, 2013b).

Drug administration

DMXBA (0, 0.3 or 1.0 mg·kg^{-1}), A-582941 (0, 0.3 or 1.0 mg·kg^{-1}) or PAM-2 (0, 0.5 or 1.0 mg·kg^{-1} for the ASST, and 0, 1.0 or 2.0 mg·kg^{-1} for the NORT) were administered intraperitoneally (IP) 30 min before testing, i.e. the acquisition trial (T1) of the NORT or first discrimination stage of the ASST. To determine receptor selectivity, DMXBA (0 or 1.0 mg·kg^{-1}) and PAM-2 (0 or 1.0 mg·kg^{-1} for the ASST, and 0 or 2.0 mg·kg^{-1} for the NORT) were administered with MLA (0 or 3.0 mg·kg^{-1}, IP) 30 min before testing. In the case of A-582941, rats received MLA (0 or 3.0 mg·kg^{-1}, IP) 30 min before the injection of the agonist (0 or 1.0 mg·kg^{-1}), and after additional 30 min, the test was performed.

For the drug interaction study, rats were simultaneously injected with inactive doses of PAM-2 (0 or 0.5 mg·kg^{-1}) and DMXBA (0 or 0.3 mg·kg^{-1} for the ASST and 0 or 0.1 mg·kg^{-1} for the NORT) or/and A-582941 (0 or 0.1 mg·kg^{-1}) 30 min prior to testing. To determine receptor selectivity, MLA (3.0 mg·kg^{-1}) was administered with DMXBA and PAM-2 and after additional 30 min, the test was performed. In the case of A-582941, rats received MLA (3.0 mg·kg^{-1}) 30 min before the co-injection of the agonist and PAM-2. In the scopolamine study, PAM-2 (1.0 and 2.0 mg·kg^{-1}) was administrated IP, followed 30 min later by IP administration of scopolamine 1.25 mg·kg^{-1}, and after additional 30 min, the test was performed.

Previous in vivo studies indicate that the IP administration of 1 μmol·kg^{-1} (~0.3 mg·kg^{-1}) of A-582941 produces a maximal concentration of 300 ng/g (~1 μM) in the brain, which is enough to activate α7 AChRs (Tietje *et al.*, 2008). The oral administration of DMXBA at a dose of 10 mg·kg^{-1} produces a peak concentration of 664 ng/g (>2 μM) in the brain (Mahnir *et al.*, 1998). The IP administration of 6.2 μmol·kg^{-1} of MLA produces maximal brain levels of ~50-100 nM, which is enough to inhibit α7 AChRs (Turek *et al.*, 1995). In addition, our initial pharmacokinetics experiments indicate that a brain concentration of ~0.2 μM of PAM-2 is attained after the acute injection of 1.0 mg·kg^{-1} of the compound (unpublished results), which is enough to modulate α7 AChRs.

Statistical analysis

ASST. The number of trials required to achieve the criterion of 6 consecutive correct responses was recorded for each rat and for each discrimination phase of the ASST. Data presented in Figures 1a-c and Figures 5a-b were calculated using two-way mixed-design ANOVAs with the treatment as a between-subject factor and the discrimination phase as a repeated measure. For the antagonist studies (Figs. 3a-c), data were analysed using three-way mixed-design ANOVAs with MLA and the respective drug treatment as between-subject factors and the discrimination phase as a repeated measure.

NORT. Data on exploratory preference were analysed using two-way (or three-way for the MLA studies) mixed-design ANOVAs with the respective drug treatment as between-subject factors and the object as a repeated measure. DI data were analysed by one-way (or two-way for the MLA studies) ANOVAs. Since the analyses of exploration time during retention trial (T2) and DI yielded the same results, only DI data were presented. Distance travelled was analysed using mixed-design ANOVAs (two- or three-way for the MLA studies) with the respective drug treatments as between-subject factors and trial as a repeated measure. Since there were no significant differences in the time spent exploring two identical objects in the acquisition phase in any drug-treated group and no significant treatment effects on the distance travelled by rats in the familiarisation and retention trials, these data are not presented.

Post hoc comparisons were performed using the Newman-Keuls test. The α-value was set at $P<0.05$ level. The data fulfilled criteria of normal distribution. Statistical analyses were performed with the use of Statistica 10.0 for Windows.

Electrophysiological measurements in SH-SY5Y-α7 cells

The human neuroblastoma SH-SY5Y cells were first stably transfected with the human α7 subunit expression plasmid using the SuperFect kit (Quiagen, Hilden, Germany) according to the manufacturer's instruction. Neomycin selection was initiated 48 h after transfection with

0.3 mg·ml^{-1} and reduced to 0.1 mg·ml^{-1} after appearance of single clones. About 10 SH-SY5Y cell clones from this transfection showed specific ^{125}I-α-bungarotoxin binding of >70%.

The SH-SY5Y-α7 cells overexpressing the α7 AChR were cultured as described in Arias et al. (2011). More precisely, the cells were cultured in Dulbecco's Modified Eagle's Medium supplemented with 10% (v/v) FBS and 100 μg ml-1 geneticin. The cells were cultured at 37 °C, 5% CO2 and 95% relative humidity, and passaged every 3 days by detaching the cells from the cell culture flask by washing with phosphate-buffered saline and brief incubation (~3 min) with trypsin (0.5 mg·ml^{-1})/EDTA (0.2 mg·ml^{-1}).

The patch-clamp recordings were subsequently performed at room temperature in the whole-cell configuration. During the experiments the cells were continuously perfused at 5 mL/min with standard solution (i.e., 145 mM NaCl, 5 mM KCl, 1 mM $CaCl_2$, 5 mM HEPES, 5 mM glucose, and 20 mM sucrose, the pH was adjusted to 7.4 with NaOH). Patch electrodes had a resistance of 3-5 MΩ and were filled with 140 mM KCl, 5 mM HEPES, 5 mM EGTA, 3 mM $MgCl_2$, and 2 mM Na_2ATP (the pH was adjusted to 7.2 with KOH). Cells were voltage clamped at -60 mV and access resistance was monitored throughout the recordings. Currents were amplified with an Axopatch 1D amplifier, filtered at 5 kHz, and digitized at 10 kHz. Drugs were applied directly by gravity through a Y-tube perfusion system. Drug application had a fast onset and achieved a complete local perfusion of the recorded cell. Application of 3 μM DMXBA produced a current characterized by a peak and its concomitant plateau that is reached after few milliseconds. Subsequently, the agonist and different concentrations of PAM-2 (i.e., 1-300 μM) were applied, producing larger currents.

The concentration-potentiation relationship for PAM-2 was determined by using non-linear regression (GraphPad-Prism software, CA, USA), by fitting the experimental data into the modified Hill equation:

$$I_{PAM-2} / I_{DMXBA} = 1 / [1 + (\text{apparent } EC_{50}/[PAM-2])^{n_H}] \qquad (1)$$

where I_{DMXBA} is the response to 3 μM DMXBA, I_{PAM-2} is the response to 3 μM DMXBA in the presence of different concentrations of PAM-2 (i.e., [PAM-2]), apparent EC_{50} is the concentration of PAM-2 producing half-maximal potentiation, and n_H is the Hill coefficient.

Results

The procognitive effects of DMXBA, A-582941 and PAM-2.

Attentional set-shifting task

Two-way mixed-design ANOVAs revealed significant interactions between the discrimination phase and respective drug treatment: $F[12,90]=22.39$, $p<0.001$ (DMXBA, Fig. 1a), $F[12,90]=6.01$, $p<0.001$ (A-582941, Fig. 1b) and $F[12,90]=13.99$, $p<0.001$ (PAM-2, Fig. 1c).

Pos-hoc analysis revealed that the acute administration of DMXBA (1.0 mg·kg^{-1}, Fig. 1a), A-582941 (0.3 and 1.0 mg·kg^{-1}, Fig. 1b), and PAM-2 (1.0 mg·kg^{-1}, Fig. 1c) significantly and specifically enhanced rats' cognitive flexibility, as indicated by a reduced number of trials to criterion during the ED stage of the ASST. There was no significant drug effect during any other discrimination stage.

Novel object recognition task

In the retention trial, vehicle-treated rats did not discriminate the novel object from the familiar one and this time-induced natural forgetting was ameliorated by DMXBA (Fig. 2a), A-582941 (Fig. 2b), and PAM-2 (Fig. 2c). Accordingly, one-way ANOVAs revealed a significant effect of drug treatment on the DI measures: $F[2,24]=10.85$, $p<0.001$ (DMXBA, Fig. 2a), $F[2,24]=14.71$, $p<0.001$ (A-582941, Fig. 2b), and $F[2,24]=16.38$, $p<0.001$ (PAM-2, Fig. 2c). Post hoc analyses demonstrated that DMXBA (0.3 and 1.0 mg·kg^{-1}, Fig. 2a), A-582941 (0.3 and 1.0 mg·kg^{-1}, Fig. 2b), and PAM-2 (1.0 and 2.0 mg·kg^{-1}, Fig. 2c) significantly increased DI compared to the controls.

The α7 nAChR antagonist, methyllycaconitine, reverses the procognitive effects of DMXBA, A-582941, and PAM-2.

Attentional set-shifting task

The selective α7 nAChR antagonist, MLA (3.0 mg·kg^{-1}), blocked the procognitive effects of active doses of DMXBA (1.0 mg·kg^{-1}, Fig. 3a), A-582941 (1.0 mg·kg^{-1}, Fig. 3b), and PAM-2 (1.0 mg·kg^{-1}, Fig. 3c). However, MLA did not affect performance at any of the ASST stages when co-administered with a vehicle. Three-way mixed-design ANOVAs revealed significant interactions among the discrimination phase, MLA and the respective drug treatment: $F[6,120]=14.91$, $p<0.001$ (DMXBA, Fig. 3a), $F[6,120]=12.56$, $p<0.001$ (A-582941, Fig. 3b), and $F[6,120]=12.56$, $p<0.001$ (PAM-2, Fig. 3c).

Novel object recognition task

As shown in Figure 4a-c, the DI in rats co-treated with MLA (3.0 mg·kg^{-1}) and either DMXBA (1.0 mg·kg^{-1}), A-582941 (1.0 mg·kg^{-1}), or PAM-2 (2.0 mg·kg^{-1}) was significantly lower than that in groups treated with the respective compound alone. Thus, MLA blocked the procognitive effects of the tested compounds. Two-way ANOVA interactions between MLA and the respective drug treatment revealed the following results: $F[1,34]=7.14$, $p<0.05$ (DMXBA, Fig. 4a), $F[1,34]=21.19$, $p<0.001$ (A-582941, Fig. 4b), and $F[1,34]=11.42$, $p<0.01$, (PAM-2, Fig. 4c).

The co-administration of inactive doses of PAM-2 with either DMXBA or A-582941 facilitates cognitive performance.

Attentional set-shifting task

The co-administration of inactive doses of PAM-2 (0.5 mg·kg^{-1}) with either DMXBA (0.3 mg·kg^{-1}; Fig. 5a) or A-582941 (0.1 mg·kg^{-1}; Fig. 5b) to rats reduced the number of trials to criterion in the ED phase as compared to the vehicle/vehicle-treated group and to the vehicle/DMXBA- (Fig. 5a) or vehicle/A-582941-treated (Fig. 5b) groups. The procognitive effects of the drug combinations were blocked by MLA (Figs. 5a-b), indicating that the observed effects are α7 nAChR-dependent.

Novel object recognition task.

The co-administration of inactive doses of PAM-2 (0.5 mg·kg^{-1}) with either DMXBA (0.1 mg·kg^{-1}, Fig. 6a) or A-582941 (0.1 mg·kg^{-1}, Fig. 6b) augmented the rats' ability to discriminate the novel object from the familiar object in the retention trial. The DI in rats co-treated with PAM-2 and either DMXBA ($F[5,54]=9.31$, $p<0.001$, Fig. 6a) or A-582941 ($F[5,54]=25.35$, $p<0.001$, Fig. 6b) was significantly higher than that for the vehicle-treated (control) and drug (alone)-treated rats. Interestingly, MLA (3.0 mg·kg^{-1}) blocked the procognitive effects of the drug combinations (Figs. 6a-b).

PAM-2 reverses the scopolamine-induced object recognition deficit.

As demonstrated in Figure 7, the administration of scopolamine abolished the ability to discriminate novel and familiar objects (one-way ANOVA: F[3.36]=18.41, p<0.001). PAM-2 (1.0 and 2.0 mg·kg^{-1}) significantly attenuated the observed scopolamine-induced DI reduction.

PAM-2 enhances the α7 nAChR activity elicited by DMXBA.

The electrophysiological results indicated that PAM-2 enhances the activity elicited by a fixed concentration (3 μM) of DMXBA, a selective α7 nAChR partial agonist (Fig. 8). The observed plateau current elicited by 3 μM DMXBA on α7 nAChRs was considered the control value (I_{DMXBA}). Increasing concentrations of PAM-2 (i.e., 1-300 μM) potentiated the initial current (I_{PAM-2}), reaching an E_{max} value of 225 ± 5 %. This value is practically the same as that determined by Ca^{2+} influx experiments (204 ± 13 %), where (±)-epibatidine was used as the agonist (Arias *et al.*, 2011). The concentration-response curve gave an apparent potentiating EC$_{50}$ value of 34 ± 3 μM, which is larger than that determined previously by Ca^{2+} influx assays (~5 μM; (Arias *et al.*, 2011). Several possible causes might account for this difference: (1) methodological differences between the used electrophysiological (this paper) and Ca^{2+} influx (Arias *et al.*, 2011) techniques, (2) the use of different cell types: GH3-α7 cells for the Ca^{2+} influx assays (Arias *et al.*, 2011) vs. the SH-SY5Y-α7 cells for this study, (3) the use of a very low initial concentration of (±)-epibatidine (EC$_5$ = 20 nM) for the Ca^{2+} influx experiments (Arias *et al.*, 2011) compared to the used concentration of DMXBA (3 μM) which corresponds approximately to its EC$_{25}$ value (Papke & Porter Papke, 2002). This possibility is supported by the fact that at a higher concentration of DMXBA (10 μM), the potentiation elicited by 100 μM PAM-2 was 175 ± 28 % (n = 4), a value slightly lower than that using 3 μM DMXBA (i.e., 212 ± 20 %; see Fig. 8), and finally, (3) that the used PAM-2 was synthetized by a new method which rends molecules with slightly less activity (Bagdas *et al.*, 2015). On the other hand, the fact that the calculated n$_H$ value (1.71 ± 0.23) is higher than unity suggests cooperative interactions for PAM-2, as was described previously (Arias *et al.*, 2011;Bagdas *et al.*, 2015).

Discussion

The present study demonstrate that PAM-2, a selective α7 nAChR PAM, as well as DMXBA and A-582941, selective α7 nAChR agonists, facilitate cognitive flexibility, as assessed by the ASST, and attenuate the delay-induced impairment in NORT performance in rats. Since MLA, a selective α7 nAChR competitive antagonist, fully blocked the procognitive effects mediated by the tested compounds, we inferred that the observed activities are mediated by α7 nAChRs. Interestingly, the co-injection of inactive doses of PAM-2 and DMXBA or A-582941 also improved rats' performance on the ASST and NORT in a MLA-dependent manner, suggesting agonist-PAM synergism.

The observed effects of α7 nAChR ligands in the ASST corroborate previous results suggesting an involvement of the nicotinic receptor system in processes underlying cognitive flexibility. Accordingly, Allison and Shoahib (2013) demonstrated that either sub-chronic or acute administration of nicotine improves rat performance on the ASST. Although α7-/- mice did not demonstrate impaired performance on the ASST (Young *et al.*, 2011), recent preclinical data suggest that an approach based on α7 nAChR stimulation may be useful in treating schizophrenia-like cognitive inflexibility in the neurodevelopmental or NMDA receptor blockade-based model. Likewise, acute administration of RG3487 and SSR180711,

α7 nAChR partial agonists, reversed ED deficits in rats sub-chronically treated with the NMDA receptor antagonist, phencyclidine (Wallace *et al.*, 2011), and in rats with transient inactivation of the neonatal ventral hippocampus (Brooks *et al.*, 2012), respectively. DMXBA, used in our experiments, has been also demonstrated to be effective in alleviating dizocilpine-evoked deficits in a rat maze-based strategy set-shifting paradigm (Jones *et al.*, 2014). However, the active dose of DMXBA was much higher (i.e., 30 mg·kg^{-1}) than that used in the current experiments (i.e., 1.0 mg·kg^{-1}). This discrepancy may arise from differences in the applied paradigm (perceptual vs strategy set shifting) or in the testing condition (cognitively unimpaired vs impaired animals). In addition, such high doses may produce enough endogenous concentrations to inhibit non-α7 AChRs. To our knowledge, A-582941 has not been evaluated in any set-shifting procedure.

Less is known about the effects of α7 nAChR PAMs on set-shifting performance, and the only published data in this regard concern to PNU-120596. This type II α7-selective PAM was effective in reversing sub-chronic phencyclidine-induced ED set-shifting deficits on the ASST (McLean *et al.*, 2012). Hence, our study supports the involvement of α7 nAChRs in the modulation of cognitive flexibility by demonstrating that selective agonists, DMXBA and A-582941, as well as PAM-2, a selective α7-PAM, facilitate set-shifting performance in cognitively unimpaired control rats. These effects were blocked by MLA, a selective α7 nAChR competitive antagonist, supporting the notion that the observed drug activities are mediated by α7 nAChRs. However, a direct comparison of our findings to other studies is not possible because most of the previous experiments did not include α7 nAChR agonist-treated control rats (Jones *et al.*, 2014;McLean *et al.*, 2012;Wallace *et al.*, 2011). Since relatively high levels of performance were achieved in those studies (Brooks *et al.*, 2012), further improvement could not be accomplished.

Our results also demonstrated that the efficacy of PAM-2 to enhance rats' object recognition memory is comparable to those mediated by the partial agonists, DMXBA and A-582941. The effectiveness of α7 nAChR agonists has been widely documented in NORT studies (Lyon *et al.*, 2012). In line with our data, Callahan et al. (2014) demonstrated that DMXBA (1-10 mg·kg^{-1}) enhanced rats' object recognition memory at the 48 h delay and that this effect was antagonised by MLA in a dose-dependent manner (1.25 and 5 mg·kg^{-1}). Moreover, A-582941 (at doses <0.3 mg·kg^{-1}) improved recognition memory in the social discrimination task in rats (Bitner *et al.*, 2007).

Although α7 nAChR PAMs have been demonstrated to be effective against the pharmacologically induced deficits of object recognition (Pandya & Yakel, 2013;Eskildsen *et al.*, 2014), the restoration of delay-induced forgetting by this class of compounds has not been demonstrated. In contrast to the effectiveness of PAM-2 in alleviating spontaneous forgetting, Callahan et al. (2013) showed that PNU-120596 did not have a significant effect on Sprague-Dawley rats' NORT performance when tested with a 48 h delay. However, the combination of PNU-120596 with a subthreshold dose of donepezil, an acetylcholinesterase inhibitor used for the treatment of AD, reversed delay-induced forgetting in that task (Callahan *et al.*, 2013).

Our result also demonstrated that PAM-2 reversed object recognition impairment induced by scopolamine, a pharmacological model of cholinergic deficits known to be associated with AD. These results are corroborated by the previous study demonstrating that PAM-2 was also effective against the scopolamine-induced impairment in the passive avoidance test in mice (Targowska-Duda *et al.*, 2014b). In line with these data, PNU-120596 restored object recognition memory in scopolamine treated rats (Pandya & Yakel, 2013), and another α7

nAChR PAM, NS-1738, reversed scopolamine-induced deficits in the Morris water maze task in rats (Timmermann *et al.*, 2007). Several studies demonstrated the efficacies of α7 nAChR agonists against AD-like pathology. For example, DMXB ameliorated the spatial memory deficits induced by intracerebroventricular injection of β-amyloid25–35 to mice (Chen *et al.*, 2010). Moreover, A-582941 restored learning and memory in aged 3xTg-AD mice with robust AD-like pathology (Medeiros *et al.*, 2014). Determining the efficacy of α7 nAChR PAMs awaits further studies.

The electrophysiological results indicated that PAM-2 potentiates DMXBA-evoked α7 nAChR activity. Studies in hippocampal interneurons demonstrated that either PAM-2 (Arias, submitted paper) or PNU-120596 (Lopez-Hernandez et al., 2009) potentiates the activity of 4OH-DMXBA, an active DMXBA metabolite with selectivity for the α7 nAChR. These results fit very well with our behavioural results showing that the co-administration of an inactive dose of PAM-2 with either DMXBA or A-582941 enhanced cognitive flexibility and recognition memory in rats in a MLA-dependent manner. Our results in the NOR test, in turn, are in agreement with studies using passive avoidance tests, showing that PAM-2 improves memory consolidation and that nicotine potentiates the promnesic activity elicited by PAM-2 (Targowska-Duda *et al.*, 2014b). Taking together, these results support the view that the procognitive and promnesic activity elicited by PAM-2 alone or in combination with agonists are mediated by α7 nAChRs.

One may notice that the dose response-relationship to PAM-2 is very steep. A similar trend was observed for the activity of PAM-2 on memory acquisition determined by the passive avoidance test (Targowska-Duda *et al.*, 2014b). More precisely, 1.0, but not 0.5, $mg \cdot kg^{-1}$ of PAM-2 increased memory acquisition. Likewise, another α7 nAChR PAM, CCMI, exerted procognitive effects at a dose of 1 $mg \cdot kg^{-1}$ but was inactive when administered at a dose of 0.3 $mg \cdot kg^{-1}$ (Nikiforuk *et al.*, 2015). Nevertheless, the dose of 0.5 $mg \cdot kg^{-1}$ PAM-2 was effective when co-administered with α7 nAChR agonists. A possibility is that the attained brain concentration at 0.5 $mg \cdot kg^{-1}$ PAM-2 is not enough to modulate endogenous ACh-activated α7 AChRs. Alternatively, the cognitive-enhancing effects of a lower dose of PAM-2 may be revealed in cognitively-impaired animals, in which the level of performance is low enough to allow for further improvement.

A wide body of evidence suggests that α7 nAChRs are involved in the modulation of the release of a number of neurotransmitters that have been implicated in cognitive functions such as glutamate, GABA, and dopamine (Bencherif *et al.*, 2012). Alternatively, stimulation of α7 nAChRs may activate signalling pathways known to be involved in cognitive functions. For example, Bitner et al. (2007) demonstrated that the procognitive efficacy of A-582941 correlates with increases in extracellular-signal regulated kinase 1/2 (ERK1/2) and cAMP response element-binding protein (CREB) phosphorylation. Interestingly, the chronic treatment with 0.5 $mg \cdot kg^{-1}$ PAM-2 also increases ERK1/2 phosphorylation in the mouse hippocampus, a brain area involved in memory and cognition (paper in preparation).

The present study demonstrates the role of α7 nAChRs on recognition memory and cognitive flexibility in rat preclinical tasks, as well as the ability of α7 nAChR ligands to enhance these important functions. The procognitive efficacy of PAM-2 is comparable to those of orthosteric agonists. Thus, PAM-2, alone or in combination with lower doses of selective agonists, likely represents a useful pharmacological approach for cognitive enhancement. The compound's efficacy against disease-like cognitive impairments awaits further studies.

Conflict of interest

None

Authors Contributions:

AP, AN and TK carried out behavioural tests. FR and GP performed electrophysiological study. AN, HRA and PP conceived the study. AN and HRA wrote the first draft of the manuscript. PP contributed to the final version of the manuscript.

Fig. 1: DMXBA (a), A-582941 (b), and PAM-2 (c) improve attentional set-shifting.

DMXBA (0, 0.3 or 1.0 mg·kg^{-1}), A-582941 (0, 0.3 or 1.0 mg·kg^{-1}), or PAM-2 (0, 0.5 or 1.0 mg·kg^{-1}) was administrated IP 30 min before testing. The results represent the mean ± S.E.M. of a number of trials required to reach the criterion of 6 consecutive correct trials for each of the discrimination phases i.e., simple discrimination (SD), compound discrimination (CD), reversal 1 (Rev1), intradimensional shift (ID), reversal 2 (Rev 2), extradimensional shift (ED) and reversal 3 (Rev 3). N = 6 rats per group. ***p<0.001 and **p<0.01, significant improvement in ED performance compared to that for the vehicle-treated group.

Fig. 2: DMXBA (a), A-582941 (b), and PAM-2 (c) improve novel object recognition.

DMXBA (0, 0.3 or 1.0 mg·kg^{-1}), A-582941 (0, 0.3 or 1.0 mg·kg^{-1}), or PAM-2 (0, 1.0 or 2.0 mg·kg^{-1}) was administrated IP 30 min before T1 (acquisition trial). T2 (retention trial) was performed 24 h after T1. Data are shown as the mean ± S.E.M. of discrimination index (DI) during T2. N = 7-10 rats per group. ***p<0.001, **p<0.01, and *p<0.05, significant increase in DI compared to that for the vehicle-treated group.

Fig. 3: Methyllycaconitine reverses the facilitation of attentional set-shifting elicited by DMXBA (a), A-582941 (b), and PAM-2 (c).

Methyllycaconitine (MLA; 0 or 3.0 mg·kg^{-1}, IP) was co-administered with DMXBA (0 or 1.0 mg·kg^{-1}, IP), A-582941 (0 or 1.0 mg·kg^{-1}, IP), or PAM-2 (0 or 1.0 mg·kg^{-1}, IP), 30 min before testing. The results represent the mean ± S.E.M. number of trials required to reach the criterion of 6 consecutive correct trials for each of the discrimination phases i.e., simple discrimination (SD), compound discrimination (CD), reversal 1 (Rev1), intradimensional shift (ID), reversal 2 (Rev 2), extradimensional shift (ED) and reversal 3 (Rev 3). N = 6 rats per group. ***p<0.001, significant improvement in ED performance compared to that for the vehicle-treated group. ###p<0.001, significant reduction in ED performance compared to that for the DMXBA (a)-, A-582941 (b)-, or PAM-2 (c)-treated group.

Fig. 4 Methyllycaconitine reverses the improvement of novel object recognition elicited by DMXBA (a), A-582941 (b), and PAM-2 (c).

Methyllycaconitine (MLA; 0 or 3.0 mg·kg^{-1}, IP) was co-administered with DMXBA (0 or 1.0 mg·kg^{-1}, IP), A-582941 (0 or 1.0 mg·kg^{-1}, IP), or PAM-2 (0 or 2.0 mg·kg^{-1}, IP) 30 min before T1 (acquisition trial). T2 (retention trial) was performed 24 h after T1. Data are shown as the mean ± S.E.M of discrimination index (DI) during T2. N = 9-10 rats per group. ***p<0.001, significant increase in DI compared to that for the vehicle-treated group. ###p<0.001, significant reduction in DI compared to that for the DMXBA (a)-, A-58294 (b)-, or PAM-2 (c)-treated group.

Fig. 5: The co-administration of inactive doses of PAM-2 with either DMXBA (a) or A-582941 (b) facilitates attentional set-shifting.

PAM-2 (0 or 0.5 mg·kg^{-1}) was co-injected with DMXBA (0 or 0.3 mg·kg^{-1}) or A-582941 (0 or 0.1 mg·kg^{-1}) 30 min before testing. Results represent the mean ± S.E.M. of a number of trials required to reach the criterion of 6 consecutive correct trials for each of the discrimination phases, i.e., simple discrimination (SD), compound discrimination (CD), reversal 1 (Rev1), intradimensional shift (ID), reversal 2 (Rev 2), extradimensional shift (ED) and reversal 3 (Rev 3). N = 6 rats per group. ***p<0.001, significant improvement in ED performance compared to that for the vehicle/vehicle-treated group. ###p<0.001, significant improvement in ED performance compared to that for the vehicle+DMXBA (a)- and vehicle+A-582941 (b)-treated group. +++p<0.001, significant reduction in ED performance compared to that for the PAM-2+DMXBA (a)- or PAM-2+A-58294 (b)-treated group.

Fig. 6: The co-administration of inactive doses of PAM-2 with either DMXBA (a) or A-582941 (b) facilitates novel object recognition memory.

PAM-2 (0 or 0.5 mg·kg[-1]) was co-injected with DMXBA (0 or 0.1 mg·kg[-1]) or A-582941 (0 or 0.1 mg·kg[-1]) 30 min before T1 (acquisition trial). T2 (retention trial) was performed 24 h after T1. Data are shown as the mean ± S.E.M. of discrimination index (DI) during T2. Symbols: ***p<0.001 significant increase in DI compared to that for the vehicle-treated group; ###p<0.001 significant increase in DI compared to that for the vehicle/DMXBA (a)- or vehicle/A-582941 (b) - group. +++p<0.001, significant reduction in DI compared to that for the PAM-2+DMXBA (a)- or PAM-2+A-582941 (b)-treated group.

Fig. 7: PAM-2 reverses the scopolamine-induced deficits in novel object recognition.

PAM-2 (1.0 and 2.0 mg·kg^{-1}) was administrated IP, followed 30 min later by IP administration of scopolamine (SCOP; 1.25 mg·kg^{-1}). T1 (acquisition trial) was performed 30 min after scopolamine administration, and T2 (retention trial) was performed 60 min after T1. Data are shown as the mean ± S.E.M. of discrimination index (DI) during T2. ***$p<0.001$, significant reduction in DI compared to that for the vehicle-treated group. ###$p<0.001$ and #$p<0.05$, significant increase in DI compared to that for the SCOP-treated group.

Fig. 8: PAM-2 enhances DMXBA-evoked α7 nAChR currents.

SH-SY5Y-α7 cells were initially treated with a fixed concentration of DMXBA (3 μM) (n = 27), and the observed plateau current was considered the control (IDMXBA). To determine the potentiating effect of PAM-2, increasing concentrations of PAM-2 (1-300 μM; n = 4-8) were tested on the DMXBA-evoked α7 AChR currents (IPAM-2). The concentration-response data were analysed by non-linear regression, according to Eq. (1). The results indicated that PAM-2 potentiates DMXBA-evoked α7 AChR currents with apparent EC50 = 34 ± 3 μM, Emax = 225 ± 5 %, nH = 1.71 ± 0.23, and goodness of fit r2 = 0.997.

Reference List

Alexander, SP, Benson, HE, Faccenda, E, Pawson, AJ, Sharman, JL, Spedding, M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: ligand-gated ion channels. *Br J Pharmacol*, **170**, 1582-1606.

Alexander, SP, Benson, HE, Faccenda, E, Pawson, AJ, Sharman, JL, McGrath, JC, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: overview. *Br J Pharmacol*, **170**, 1449-1458.

Allison, C & Shoaib, M. (2013). Nicotine improves performance in an attentional set shifting task in rats. *Neuropharmacology*, **64**, 314-320.

Arias, HR. (2011). Allosteric modulation of nicotine acetylcholine receptors. In Pharmacology of Nicotinic Acetylcholine Receptors from the Basic and Therapeutic Perspectives. ed. H.R.Arias, E. pp. 151-173. Research Signpost: Kerala, India.

Arias, HR, Gu, RX, Feuerbach, D & Wei, DQ. (2010). Different interaction between the agonist JN403 and the competitive antagonist methyllycaconitine with the human α7 nicotinic acetylcholine receptor. *Biochemistry*, **49**, 4169-4180.

Arias, HR, Targowska-Duda, KM, Feuerbach, D & Jozwiak, K. (2015). The antidepressant-like activity of nicotine, but not of 3-furan-2-yl-N-p-tolyl-acrylamide, is regulated by the nicotinic receptor β4 subunit. *Neurochem. Int.*, in press

Arias, HR, Gu, RX, Feuerbach, D, Guo, BB, Ye, Y & Wei, DQ. (2011). Novel positive allosteric modulators of the human α7 nicotinic acetylcholine receptor. *Biochemistry*, **50**, 5263-5278.

Bagdas, D, Targowska-Duda, KM, Lopez, JJ, Perez, EG, Arias, HR & Damaj, MI. (2015). Antinociceptive and anti-inflammatory properties of 3-furan-2-yl-N-p-tolyl-acrylamide (PAM-2), a positive allosteric modulator of α7 nicotinic acetylcholine receptors, in mice. *Anesth Analg*. in press

Bencherif, M, Stachowiak, MK, Kucinski, AJ & Lippiello, PM. (2012). α7 nicotinic cholinergic neuromodulation may reconcile multiple neurotransmitter hypotheses of schizophrenia. *Med Hypotheses*, **78**, 594-600.

Birrell, JM & Brown, VJ. (2000). Medial frontal cortex mediates perceptual attentional set shifting in the rat. *J Neurosci*, **20**, 4320-4324.

Bitner, RS, Bunnelle, WH, Anderson, DJ, Briggs, CA, Buccafusco, J, Curzon, P, et al. (2007). Broad-spectrum efficacy across cognitive domains by α7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. *J Neurosci*, **27**, 10578-10587.

Brooks, JM, Pershing, ML, Thomsen, MS, Mikkelsen, JD, Sarter, M & Bruno, JP. (2012). Transient inactivation of the neonatal ventral hippocampus impairs attentional set-shifting behavior: reversal with an α7 nicotinic agonist. *Neuropsychopharmacology*, **37**, 2476-2486.

Callahan, PM, Terry, AV, Jr. & Tehim, A. (2014). Effects of the nicotinic α7 receptor partial agonist GTS-21 on NMDA-glutamatergic receptor related deficits in sensorimotor gating and recognition memory in rats. *Psychopharmacology (Berl)*, **231**, 3695-3706.

Callahan, PM, Hutchings, EJ, Kille, NJ, Chapman, JM & Terry, AV, Jr. (2013). Positive allosteric modulator of α7 nicotinic-acetylcholine receptors, PNU-120596 augments the effects of donepezil on learning and memory in aged rodents and non-human primates. *Neuropharmacology*, **67**, 201-212.

Chen, L, Wang, H, Zhang, Z, Li, Z, He, D, Sokabe, M & Chen, L. (2010). DMXB (GTS-21) ameliorates the cognitive deficits in beta amyloid(25-35(-)) injected mice through preventing the dysfunction of alpha7 nicotinic receptor. *J Neurosci Res*, **88**, 1784-1794.

Ennaceur, A & Delacour, J. (1988). A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. *Behav Brain Res*, **31**, 47-59.

Eskildsen, J, Redrobe, JP, Sams, AG, Dekermendjian, K, Laursen, M, Boll, JB, et al. (2014). Discovery and optimization of Lu AF58801, a novel, selective and brain penetrant positive allosteric modulator of alpha-7 nicotinic acetylcholine receptors: Attenuation of subchronic phencyclidine (PCP)-induced cognitive deficits in rats following oral administration. *Bioorg Med Chem Lett*, **24**, 288-293.

Freedman, R. (2014). α7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia. *Annu Rev Med*, **65**, 245-261.

Jones, KM, McDonald, IM, Bourin, C, Olson, RE, Bristow, LJ & Easton, A. (2014). Effect of alpha7 nicotinic acetylcholine receptor agonists on attentional set-shifting impairment in rats. *Psychopharmacology (Berl)*, **231**, 673-683.

Lopez-Hernandez, GY, Thinschmidt, JS, Morain, P, Trocme-Thibierge, C, Kem, WR, Soti, F & Papke, RL. (2009). Positive modulation of alpha7 nAChR responses in rat hippocampal interneurons to full agonists and the alpha7-selective partial agonists, 4OH-GTS-21 and S 24795. *Neuropharmacology*, **56**, 821-830.

Lyon, L, Saksida, LM & Bussey, TJ. (2012). Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models. *Psychopharmacology (Berl)*, **220**, 647-672.

Mahnir, V, Lin, B, Prokai-Tatrai, K & Kem, WR. (1998). Pharmacokinetics and urinary excretion of DMXBA (GTS-21), a compound enhancing cognition. *Biopharm Drug Dispos*, **19**, 147-151.

McLean, SL, Idris, NF, Grayson, B, Gendle, DF, Mackie, C, Lesage, AS, et al. (2012). PNU-120596, a positive allosteric modulator of alpha7 nicotinic acetylcholine receptors, reverses a sub-chronic phencyclidine-induced cognitive deficit in the attentional set-shifting task in female rats. *J Psychopharmacol*, **26**, 1265-1270.

Medeiros, R, Castello, NA, Cheng, D, Kitazawa, M, Baglietto-Vargas, D, Green, KN, et al. (2014). α7 Nicotinic receptor agonist enhances cognition in aged 3xTg-AD mice with robust plaques and tangles. *Am J Pathol*, **184**, 520-529.

Nikiforuk, A, Golembiowska, K & Popik, P. (2010). Mazindol attenuates ketamine-induced cognitive deficit in the attentional set shifting task in rats. *Eur Neuropsychopharmacol*, **20**, 37-48.

Nikiforuk, A, Kos, T, Potasiewicz, A & Popik, P. (2015). Positive allosteric modulation of alpha 7 nicotinic acetylcholine receptors enhances recognition memory and cognitive flexibility in rats. *Eur Neuropsychopharmacol*. doi: 10.1016/j.euroneuro.2015.04.018.

Nikiforuk, A, Kos, T, Fijal, K, Holuj, M, Rafa, D & Popik, P. (2013). Effects of the selective 5-HT7 receptor antagonist SB-269970 and amisulpride on ketamine-induced schizophrenia-like deficits in rats. *PLoS One*, **8**, e66695.

Pandya, AA & Yakel, JL. (2013). Activation of the α7 nicotinic ACh receptor induces anxiogenic effects in rats which is blocked by a 5-HT(1)a receptor antagonist. *Neuropharmacology*, **70**, 35-42.

Papke, RL & Porter Papke, JK. (2002). Comparative pharmacology of rat and human alpha7 nAChR conducted with net charge analysis. *Br J Pharmacol*, **137**, 49-61.

Pohanka, M. (2012). Alpha7 nicotinic acetylcholine receptor is a target in pharmacology and toxicology. *Int J Mol Sci*, **13**, 2219-2238.

Roberts, AC, Robbins, TW & Everitt, BJ. (1988). The effects of intradimensional and extradimensional shifts on visual discrimination learning in humans and non-human primates. *Q J Exp Psychol B*, **40**, 321-341.

Targowska-Duda, KM, Feuerbach, D, Biala, G, Jozwiak, K & Arias, HR. (2014a). Antidepressant activity in mice elicited by 3-furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the α7 nicotinic acetylcholine receptor. *Neurosci Lett*, **569**, 126-130.

Targowska-Duda, KM, Budzynska, B, Jozwiak, K, Biała, G & Arias, HR. (2014b). 3-Furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of α7 nicotinic receptors produces pro-cognitive, antidepressant, and anxiolytic activities in mice. In 3rd Welcome Trust conference on Nicotinic Acetylcholine Receptors. Cambridge, UK, July 23-26, 2014.

Tietje, KR, Anderson, DJ, Bitner, RS, Blomme, EA, Brackemeyer, PJ, Briggs, CA, et al. (2008). Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties. *CNS Neurosci Ther*, **14**, 65-82.

Timmermann, DB, Gronlien, JH, Kohlhaas, KL, Nielsen, EO, Dam, E, Jorgensen, TD, et al. (2007). An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. *J Pharmacol Exp Ther*, **323**, 294-307.

Turek, JW, Kang, CH, Campbell, JE, Arneric, SP & Sullivan, JP. (1995). A sensitive technique for the detection of the alpha 7 neuronal nicotinic acetylcholine receptor antagonist, methyllycaconitine, in rat plasma and brain. *J Neurosci Methods*, **61**, 113-118.

Uteshev, VV. (2014). The therapeutic promise of positive allosteric modulation of nicotinic receptors. *Eur J Pharmacol*, **727**, 181-185.

Wallace, TL, Callahan, PM, Tehim, A, Bertrand, D, Tombaugh, G, Wang, S, et al. (2011). RG3487, a novel nicotinic alpha7 receptor partial agonist, improves cognition and sensorimotor gating in rodents. *J Pharmacol Exp Ther*, **336**, 242-253.

Williams, DK, Wang, J & Papke, RL. (2011). Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations. *Biochem Pharmacol*, **82**, 915-930.

Young, JW, Meves, JM, Tarantino, IS, Caldwell, S & Geyer, MA. (2011). Delayed procedural learning in α7 nicotinic acetylcholine receptor knockout mice. *Genes Brain Behav*, **10**, 720-733.